Treatment of the inflammatory myopathies: update and practical recommendations

Bibliography

• Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1996;40:581-6
   PubMed Web of Science ®Google Scholar
• Van der Meulen ME, Bronner IM, Hoogendijk JE, et al. Polymyositis: an overdiagnosed entity. Neurology 2003;61:316-21
   PubMed Web of Science ®Google Scholar
• Amato AA, Griggs RC. Unicorns, dragons, polymyositis, and other mythological beasts. Neurology 2003;61:288-9
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Eng J Med 1975;292:344-7
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Eng J Med 1975;292:403-7
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myositis. N Eng J Med 1991;325:1487-98
   PubMed Web of Science ®Google Scholar
• Tanimoto K, Nakano K, Kano S, et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995;22:668-74
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82
   PubMed Web of Science ®Google Scholar
• Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies with the exception of inclusion body myositis. Neuromusc Disord 2004;14:337-45
   PubMedGoogle Scholar
• Choy EH, Hoogendijk JE, Lecky B, et al. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2005;3:CD003643
   Google Scholar
• Lundberg IE. The heart in dermatomyositis and polymyositis. Rheumatology (Oxford) 2006;45 Suppl 4:iv18-iv21
   PubMedGoogle Scholar
• Fathi M, Lundberg IE. Interstitial lung disease in dermatomyositis and polymyositis. Curr Opin Rheumatol 2005;17:701-6
   PubMed Web of Science ®Google Scholar
• Bronner IM, Van der Meulen ME, De Visser M, et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 2006;65:1456-61
   PubMed Web of Science ®Google Scholar
• Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:85-6
   PubMed Web of Science ®Google Scholar
• Hengstman GJD. Advances in the immunopathophysiology of idiopathic inflammatory myopathies: not as simple as suspected. Curr Rheumatol Rep 2007;9:280-5
   PubMedGoogle Scholar
• Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664-78
   PubMed Web of Science ®Google Scholar
• Greenberg SA, Sanoudou D, Haslett JN, et al. Molecular profiles of inflammatory myopathies. Neurology 2002;59:1170-82
   PubMed Web of Science ®Google Scholar
• Greenberg SA, Brandshaw EM, Pinkus JL, et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005;65:1782-7
   PubMed Web of Science ®Google Scholar
• Bradshaw EM, Orihuela A, Mcardel SL, et al. A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007;178:547-56
   PubMed Web of Science ®Google Scholar
• Bunch TW, Worthington JW, Combs JJ, et al. Azathioprine with prednisone for polymyositis. Ann Intern Med 1980;92:365-9
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Eng J Med 1993;329:1993-2000
   PubMed Web of Science ®Google Scholar
• Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis n polymyositis and dermatomyositis. N Eng J Med 1992;326:1380-4
   PubMed Web of Science ®Google Scholar
• Miller J, Walsh Y, Saminaden S, et al. Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci 2002;199 (Suppl 1):553
   Google Scholar
• Vencovsky J, Jarosova K, Machacek S, et al. Cyclosporin A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000;29:95-102
   PubMed Web of Science ®Google Scholar
• Villalba L, Hicks JE, Adams EM, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998;41:392-9
   PubMed Web of Science ®Google Scholar
• Van der Meulen ME, Hoogendijk JE, Wokke JH, et al. Oral pulsed high-dose dexamethasone for myositis. J Neurol 2000;247:102-5
   PubMed Web of Science ®Google Scholar
• Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005;52:601-7
   PubMed Web of Science ®Google Scholar
• Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007;143:763-7
   PubMed Web of Science ®Google Scholar
• Hengstman GJD, De Bleecker JL, Feist E, et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008;59:159-63
   PubMed Web of Science ®Google Scholar
• Iannone F, Scioscia C, Falappone PC, et al. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 2006;33:1802-4
   PubMed Web of Science ®Google Scholar
• Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008;67:1670-7
   PubMed Web of Science ®Google Scholar
• Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 2007;34:1864-8
   PubMed Web of Science ®Google Scholar
• Pisoni CN, Cuadrado MJ, Khamashta MA, et al. Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford) 2007;46:516-8
   PubMed Web of Science ®Google Scholar
• Rowin J, Amato AA, Deisher N, et al. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 2006;66:1245-7
   PubMed Web of Science ®Google Scholar
• Hassan J, Van der Net JJ, Van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol 2008;27:1469-71
   PubMed Web of Science ®Google Scholar
• Martín Nalda A, Modesto Caballero C, Arnal Guimeral C, et al. Efficacy of tacrolimus [FK-506] in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases. Med Clin (Barc) 2006;127:697-701
   PubMed Web of Science ®Google Scholar
• Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005;52:2439-46
   PubMed Web of Science ®Google Scholar
• Orlandi V, Campieri C, Mosconi G, et al. Tacrolimus-associated myositis: a case report in a renal transplant patient. Transplant Proc 2004;36:708-10
   PubMed Web of Science ®Google Scholar
• Saito E, Koike T, Hashimoto H, et al. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol 2008;18:34-44
   PubMed Web of Science ®Google Scholar
• Kameda H, Nagasawa H, Ogawa H, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 2005;32:1719-26
   PubMed Web of Science ®Google Scholar
• Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007;46:124-30
   PubMed Web of Science ®Google Scholar
• Kotani T, Makino S, Takeuchi T, et al. Early intervention with corticosteroids and ciclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol 2008;35:254-9
   PubMed Web of Science ®Google Scholar
• Oryoji K, Himeji D, Nagafuji K, et al. Successful treatment of rapidly progressive interstitial pneumonia with autologous peripheral blood stem cell transplantation in a patient with dermatomyositis. Clin Rheumatol 2005;24:637-40
   PubMed Web of Science ®Google Scholar
• Guglielmi S, Merz TM, Gugger M, et al. Acute respiratory distress syndrome secondary to antisynthetase syndrome is reversible with tacrolimus. Eur Respir J 2008;31:213-7
   PubMed Web of Science ®Google Scholar
• Allanore Y, Vignaux O, Arnaud L, et al. Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging. Ann Rheum Dis 2006;65:249-52
   PubMed Web of Science ®Google Scholar
• Oka M, Raasakka T. Cardiac involvement in polymyositis. Scand J Rheumatol 1978;7:203-8
   PubMed Web of Science ®Google Scholar
• Stern R, Godbold JH, Chess Q, et al. ECG abnormalities in polymyositis. Arch Intern Med 1984;144:2185-9
   PubMedGoogle Scholar
• Varjú C, Pethö E, Kutas R, et al. The effect of physical exercise following acute disease exacerbation in patients with dermato/polymyositis. Clin Rehabil 2003;17:83-7
   PubMed Web of Science ®Google Scholar
• Chung YL, Alexanderson H, Pipitone N, et al. Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007;57:694-702
   PubMed Web of Science ®Google Scholar
• Barohn RJ, Amata AA, Sahenk Z, et al. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 1995;45:1302-4
   PubMed Web of Science ®Google Scholar
• Badrising UA, Schreuder GM, Giphart MJ, et al. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology 2004;63:2396-8
   PubMed Web of Science ®Google Scholar
• Koffman BM, Sivakumar K, Simonis T, et al. HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies. J Neuroimmunol 1998;84:139-42
   PubMed Web of Science ®Google Scholar
• Hengstman GJD, Ter Laak HJ, Van Engelen BGM, et al. Anti-Jo-1 positive inclusion body myositis with a marked and sustained clinical improvement after oral prednisone. J Neurol Neurosurg Psychiatry 2001;70:706
   PubMed Web of Science ®Google Scholar
• Quartuccio L, De Marchi G, Scott CA, et al. Treatment of inclusion body myositis with ciclosporin-A or tacrolimus: successful long-term management in patients with earlier active disease and concomitant autoimmune features. Clin Exp Rheumatol 2007;25:246-51
   PubMed Web of Science ®Google Scholar
• Souiedan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993;43:876-9
   PubMed Web of Science ®Google Scholar
• Amato AA, Barohn RJ, Jackson CE, et al. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1994;44:1516-8
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997;48:712-6
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001;56:323-7
   PubMed Web of Science ®Google Scholar
• Badrising UA, Maat/Schieman ML, Ferrari MD, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002;51:369-72
   PubMed Web of Science ®Google Scholar
• Lindberg C, Trysberg E, Tarkowski A, et al. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 2003;61:260-2
   PubMed Web of Science ®Google Scholar
• Barohn RJ, Herbelin L, Kissel JT, et al. Pilot trial of etanercept in the treatment of inclusion body myositis. Neurology 2006;66(Suppl 1):S123-4
   PubMed Web of Science ®Google Scholar
• Van de Vlekkert J, Hoogendijk JE, Frijns CJ, et al. Spontaneous recovery of dermatomyositis and unspecified myositis in three adult patients. J Neurol Neurosurg Psychiatry 2008;79:729-30
   PubMed Web of Science ®Google Scholar
• Rouster-Stevens KA, Gursahaney A, Ngai KL, et al. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum 2008;59:222-6
   PubMed Web of Science ®Google Scholar